Loading clinical trials...

A Study of 2 Doses of MAP0010 in Adult Asthmatics | Clinical Trials | Clareo Health

COMPLETEDPHASE2

A Study of 2 Doses of MAP0010 in Adult Asthmatics

A Randomized, Open Label, Active-Controlled, 4-Treatment, 2-Period, 2 Parallel Block Crossover Pharmacokinetic and Safety Study of 2 Doses of MAP0010 in Adult Asthmatics

NCT00554970•Allergan

View on ClinicalTrials.gov

Summary

The purpose of this study is to examine the blood levels of two doses of MAP0010 (a corticosteroid) and two doses of an approved corticosteroid in adult asthma and safety with twice daily dosing over 7 days.

Eligibility

Age

18 - 45 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Male or female adult asthmatics with mild to moderate persistent asthma.
•18 to 45 (up to the 46th birthday) years of age.
•Documented diagnosis of asthma at least 3 months prior to Visit 1, per NIH/NHLBI, EPR-3 criteria.
•Able to withhold short-acting bronchodilators (e.g., albuterol or ipratropium bromide) for at least 4 hours prior to clinic visits.
•Baseline FEV1 greater than or equal to 50% of predicted normal.

Exclusion Criteria

•Any other significant illness/abnormality
•A history of upper or lower respiratory tract infection within 2 weeks
•A history of acute or severe asthma attack requiring ICU admission or ventilatory support.

Locations (1)

West Coast Clinical Trials Phase 2-4, LLC

Long Beach, California, United States

Key Dates

Start Date

November 1, 2007

Primary Completion Date

January 1, 2008

Completion Date

March 1, 2008

Last Updated

January 9, 2014

Enrollment

ACTUAL participants

Conditions

Asthma

Interventions

MAP0010 low dose

DRUG

MAP0010 high dose

DRUG

Budesonide inhalation suspension 0.25mg

DRUG

Budesonide inhalation suspension 0.5mg

DRUG

NHALES (Natural History of Asthma With Longitudinal Environmental Sampling)

NCT02327897

Asthma

View study

RECRUITINGNA

Blood Eosinophil Guided Versus Usual Care In The Management Of Mild To Moderate Asthma at Primary Care (BEAM)

NCT07486401

Asthma ExacerbationsBiomarkers / Blood+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 9, 2014Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of 2 Doses of MAP0010 in Adult Asthmatics

Inclusion Criteria

Exclusion Criteria

NHALES (Natural History of Asthma With Longitudinal Environmental Sampling)

Blood Eosinophil Guided Versus Usual Care In The Management Of Mild To Moderate Asthma at Primary Care (BEAM)

A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma

Relationship of Airway Microbiota, Endotype and Phenotype in Adult Asthma

To Assess the Management of Patients on Global Initiative of Asthma (GINA) Step 4 and 5 Treatment in Hong Kong

A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma